{"id":"ganirelix","rwe":[{"pmid":"41426754","year":"2025","title":"IgA Vasculitis With Nephritis Following Controlled Ovarian Stimulation and Oocyte Donation.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41142490","year":"2025","title":"Real-World Safety and Effectiveness of Ganirelix for Ovarian Stimulation in Chinese Women: A Multicenter, Prospective, Single-Arm, Observational Study.","finding":"","journal":"Women's health reports (New Rochelle, N.Y.)","studyType":"Clinical Study"},{"pmid":"40297130","year":"2025","title":"Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study.","finding":"","journal":"Frontiers in reproductive health","studyType":"Clinical Study"},{"pmid":"40264185","year":"2025","title":"Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).","finding":"","journal":"BMC pharmacology & toxicology","studyType":"Clinical Study"},{"pmid":"40081305","year":"2025","title":"Freeze-all indications in women with subfertility undergoing IVF: a cohort study.","finding":"","journal":"Reproductive biomedicine online","studyType":"Clinical Study"}],"_fda":{"id":"fd318e79-614e-4c0e-a683-b465ab5b8386","set_id":"1f067dfb-f9c7-4020-ab7b-da2ba695ab32","openfda":{"unii":["56U7906FQW"],"route":["SUBCUTANEOUS"],"rxcui":["855200"],"spl_id":["fd318e79-614e-4c0e-a683-b465ab5b8386"],"brand_name":["Ganirelix Acetate"],"spl_set_id":["1f067dfb-f9c7-4020-ab7b-da2ba695ab32"],"package_ndc":["71288-554-80"],"product_ndc":["71288-554"],"generic_name":["GANIRELIX ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["GANIRELIX ACETATE"],"manufacturer_name":["Meitheal Pharmaceuticals Inc."],"application_number":["ANDA214996"],"is_original_packager":[true]},"version":"7","warnings":["WARNINGS Ganirelix acetate injection should be prescribed by physicians who are experienced in infertility treatment. Before starting treatment with ganirelix acetate, pregnancy must be excluded. Safe use of ganirelix acetate during pregnancy has not been established (see CONTRAINDICATIONS and PRECAUTIONS )."],"pregnancy":["Pregnancy Ganirelix acetate is contraindicated in pregnant women. When administered from Day 7 to near term to pregnant rats and rabbits at doses up to 10 and 30 mcg/day (approximately 0.4 to 3.2 times the human dose based on body surface area), ganirelix acetate increased the incidence of litter resorption. There was no increase in fetal abnormalities. No treatment-related changes in fertility, physical, or behavioral characteristics were observed in the offspring of female rats treated with ganirelix acetate during pregnancy and lactation. The effects on fetal resorption are logical consequences of the alteration in hormonal levels brought about by the antigonadotropic properties of this drug and could result in fetal loss in humans. Therefore, this drug should not be used in pregnant women (see CONTRAINDICATIONS )."],"overdosage":["OVERDOSAGE There have been no reports of overdosage with ganirelix acetate in humans."],"description":["DESCRIPTION Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix acetate is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N 9 ,N 10 -diethyl-D-homoarginyl-L-leucyl-N 9 , N 10 -diethyl-L-homoarginyl-L-prolyl-D-alanylamide acetate. The molecular weight for ganirelix acetate is 1570.4 as an anhydrous free base. The structural formula is as follows: Ganirelix Acetate Ganirelix Acetate Injection is supplied as a colorless, sterile, ready-to-use, aqueous solution intended for SUBCUTANEOUS administration only. Each single dose, sterile, prefilled syringe contains 250 mcg per 0.5 mL of ganirelix acetate; 0.1 mg glacial acetic acid, USP; 23.5 mg mannitol, USP; and water for injection, USP adjusted to pH 5.0 with glacial acetic acid, USP and/or sodium hydroxide, NF. Structural Formula"],"precautions":["PRECAUTIONS General Special care should be taken in women with signs and symptoms of active allergic conditions. Cases of hypersensitivity reactions (both generalized and local), including anaphylaxis (including anaphylactic shock), angioedema and urticaria, have been reported with ganirelix acetate, as early as with the first dose, during post-marketing surveillance (see ADVERSE REACTIONS ). If a hypersensitivity reaction is suspected, ganirelix acetate should be discontinued and appropriate treatment administered. In the absence of clinical experience, ganirelix acetate treatment is not advised in women with severe allergic conditions. The rigid needle shield of this product is not made with natural rubber/latex (see CONTRAINDICATIONS and HOW SUPPLIED ). Information for Patients Prior to therapy with ganirelix acetate, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see ADVERSE REACTIONS ). Ganirelix acetate should not be prescribed if the patient is pregnant. Laboratory Tests A neutrophil count ≥ 8.3 (x 10 9 /L) was noted in 11.9% (up to 16.8 x 10 9 /L) of all subjects treated within the adequate and well-controlled clinical trials. In addition, downward shifts within the ganirelix acetate group were observed for hematocrit and total bilirubin. The clinical significance of these findings was not determined. Drug Interactions No formal drug-drug interaction studies have been performed. Carcinogenesis and Mutagenesis, Impairment of Fertility Long-term toxicity studies in animals have not been performed with ganirelix acetate to evaluate the carcinogenic potential of the drug. Ganirelix acetate did not induce a mutagenic response in the Ames test (S. typhimurium and E. coli ) or produce chromosomal aberrations in in vitro assay using Chinese Hamster Ovary cells. Pregnancy Ganirelix acetate is contraindicated in pregnant women. When administered from Day 7 to near term to pregnant rats and rabbits at doses up to 10 and 30 mcg/day (approximately 0.4 to 3.2 times the human dose based on body surface area), ganirelix acetate increased the incidence of litter resorption. There was no increase in fetal abnormalities. No treatment-related changes in fertility, physical, or behavioral characteristics were observed in the offspring of female rats treated with ganirelix acetate during pregnancy and lactation. The effects on fetal resorption are logical consequences of the alteration in hormonal levels brought about by the antigonadotropic properties of this drug and could result in fetal loss in humans. Therefore, this drug should not be used in pregnant women (see CONTRAINDICATIONS ). Nursing Mothers Ganirelix acetate should not be used by lactating women. It is not known whether this drug is excreted in human milk. Geriatric Use Clinical studies with ganirelix acetate did not include a sufficient number of subjects aged 65 and over."],"how_supplied":["HOW SUPPLIED Ganirelix Acetate Injection is a colorless, aqueous solution of ganirelix acetate and is supplied as follows: NDC Ganirelix Acetate Injection (250 mcg per 0.5 mL) Package Factor 71288- 554 -80 Disposable, ready for use, prefilled Single-Dose Syringe containing 250 mcg per 0.5 mL of ganirelix acetate, closed with a rubber piston that does not contain latex. Each prefilled syringe is affixed with a 29 gauge x ½-inch needle closed by a rigid needle shield that is not made with natural rubber latex (see CONTRAINDICATIONS and PRECAUTIONS , General ). 1 syringe per carton Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Protect from light. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex. Brands listed are the trademarks of their respective owners. meitheal ® Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) ©2025 Meitheal Pharmaceuticals Inc. Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing, China 210061 Revised: February 2025 8H6AAM9-03"],"geriatric_use":["Geriatric Use Clinical studies with ganirelix acetate did not include a sufficient number of subjects aged 65 and over."],"effective_time":"20250220","nursing_mothers":["Nursing Mothers Ganirelix acetate should not be used by lactating women. It is not known whether this drug is excreted in human milk."],"clinical_studies":["Clinical Studies The efficacy of ganirelix acetate was established in two adequate and well-controlled clinical studies which included women with normal endocrine and pelvic ultrasound parameters. The studies intended to exclude subjects with polycystic ovary syndrome (PCOS) and subjects with low or no ovarian reserve. One cycle of study medication was administered to each randomized subject. For both studies, the administration of exogenous recombinant FSH [Follistim ® (follitropin beta for injection)] 150 IU daily was initiated on the morning of Day 2 or 3 of a natural menstrual cycle. Ganirelix acetate injection was administered on the morning of Day 7 or 8 (Day 6 of recombinant FSH administration). The dose of recombinant FSH administered was adjusted according to individual responses starting on the day of initiation of ganirelix acetate. Both recombinant FSH and ganirelix acetate were continued daily until at least three follicles were 17 mm or greater in diameter at which time hCG [Pregnyl ® (chorionic gonadotropin for injection, USP)] was administered. Following hCG administration, ganirelix acetate and recombinant FSH administration were discontinued. Oocyte retrieval, followed by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), was subsequently performed. In a multicenter, double-blind, randomized, dose-finding study, the safety and efficacy of ganirelix acetate were evaluated for the prevention of LH surges in women undergoing COH with recombinant FSH. Ganirelix acetate injection doses ranging from 62.5 mcg to 2,000 mcg and recombinant FSH were administered to 332 patients undergoing COH for IVF (see TABLE II ). Median serum LH on the day of hCG administration decreased with increasing doses of ganirelix acetate. Median serum E 2 (17β-estradiol) on the day of hCG administration was 1475, 1110, and 1160 pg/mL for the 62.5, 125, and 250 mcg doses, respectively. Lower peak serum E 2 levels of 823, 703, and 441 pg/mL were seen at higher doses of ganirelix acetate 500, 1,000, and 2,000 mcg, respectively. The highest pregnancy and implantation rates were achieved with the 250 mcg dose of ganirelix acetate as summarized in Table II . TABLE II: Results from the multicenter, double-blind, randomized, dose-finding study to assess the efficacy of ganirelix acetate to prevent premature LH surges in women undergoing COH with recombinant FSH. (Protocol 38602) * Following initiation of ganirelix acetate therapy. Includes subjects who have complied with daily injections ‡ Median values ϒ Mean (standard deviation) † ET: Embryo Transfer Ω As evidenced by ultrasound at 5–6 weeks following ET Daily Dose (mcg) of Ganirelix Acetate 62.5 mcg 125 mcg 250 mcg 500 mcg 1,000 mcg 2,000 mcg No. subjects receiving Ganirelix Acetate 31 66 70 69 66 30 No. subjects with ET † 27 61 62 54 61 27 No. of subjects with LH rise ≥ 10 mIU/mL* 4 6 1 0 0 0 Serum LH (mIU/mL) on day of hCG ‡ 5 th –95 th percentiles 3.6 0.6–19.9 2.5 0.6–11.4 1.7 < 0.25–6.4 1.0 0.4–4.7 0.6 < 0.25–2.2 0.3 < 0.25–0.8 Serum E 2 (pg/mL) on day of hCG ‡ 5 th –95 th percentiles 1475 645–3720 1110 424–3780 1160 384–3910 823 279–2720 703 284–2360 441 166–1940 Vital pregnancy rate Ω per attempt, n (%) 7 (22.6) 17 (25.8) 25 (35.7) 8 (11.6) 9 (13.6) 2 (6.7) per transfer, n (%) 7 (25.9) 17 (27.9) 25 (40.3) 8 (14.8) 9 (14.8) 2 (7.4) Implantation rate (%) ϒ 14.2 (26.8) 16.3 (30.5) 21.9 (30.6) 9.0 (23.7) 8.5 (21.7) 4.9 (20.1) Transient LH rises alone were not deleterious to achieving pregnancy with ganirelix acetate at doses of 125 mcg (3/6 subjects) and 250 mcg (1/1 subjects). In addition, none of the subjects with LH rises ≥ 10 mIU/mL had premature luteinization indicated by a serum progesterone above 2 ng/mL. A multicenter, open-label, randomized study was conducted to assess the efficacy and safety of ganirelix acetate in women undergoing COH. Follicular phase treatment with ganirelix acetate 250 mcg was studied using a luteal phase GnRH agonist as a reference treatment. A total of 463 subjects were treated with ganirelix acetate by subcutaneous injection once daily starting on Day 6 of recombinant FSH treatment. Recombinant FSH was maintained at 150 IU for the first 5 days of ovarian stimulation and was then adjusted by the investigator on the sixth day of gonadotropin use according to individual responses. The results for the ganirelix acetate arm are summarized in Table III . TABLE III: Results from the multicenter, open-label, randomized study to assess the efficacy and safety of ganirelix acetate in women undergoing COH. (Protocol 38607) * Following initiation of ganirelix acetate therapy ‡ Median values § Restricted to subjects with hCG injection ¥ Mean (standard deviation) † ET: Embryo Transfer Ω As evidenced by ultrasound at 12–16 weeks following ET λ Includes one patient who achieved pregnancy with intrauterine induction Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards Ganirelix Acetate 250 mcg No. subjects treated 463 Duration of GnRH analog (days) §, ¥ 5.4 (2.0) Duration of recombinant FSH (days) §, ¥ 9.6 (2.0) Serum E 2 (pg/mL) on day of hCG ‡ 5 th –95 th percentiles 1190 373–3105 Serum LH (mIU/mL) on day of hCG ‡ 5 th –95 th percentiles 1.6 0.6–6.9 No. of subjects with LH rise ≥ 10 mIU/mL * 13 No. of follicles > 11 mm §, ¥ 10.7 (5.3) No. of subjects with oocyte retrieval 440 No. of oocytes ¥ 8.7 (5.6) Fertilization rate 62.1% No. subjects with ET † 399 No. of embryos transferred ¥ 2.2 (0.6) No. of embryos ¥ 6.0 (4.5) Ongoing pregnancy rate Ω, § per attempt, n (%) λ 94 (20.3) per transfer, n (%) 93 (23.3) Implantation rate (%) ¥ 15.7 (29) The mean number of days of ganirelix acetate treatment was 5.4 (2–14). LH Surges The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. In 463 subjects administered ganirelix acetate injection 250 mcg, a premature LH surge prior to hCG administration, (LH rise ≥ 10 mIU/mL with a significant rise in serum progesterone > 2 ng/mL, or a significant decline in serum estradiol) occurred in less than 1% of subjects."],"laboratory_tests":["Laboratory Tests A neutrophil count ≥ 8.3 (x 10 9 /L) was noted in 11.9% (up to 16.8 x 10 9 /L) of all subjects treated within the adequate and well-controlled clinical trials. In addition, downward shifts within the ganirelix acetate group were observed for hematocrit and total bilirubin. The clinical significance of these findings was not determined."],"pharmacokinetics":["Pharmacokinetics The pharmacokinetic parameters of single and multiple injections of ganirelix acetate in healthy adult females are summarized in Table I . Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of ganirelix acetate are dose-proportional in the dose range of 125 to 500 mcg. TABLE I: Mean (SD) pharmacokinetic parameters of 250 mcg of ganirelix acetate following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days. t max Time to maximum concentration t ½ Elimination half-life C max Maximum serum concentration AUC Area under the curve; Single dose: AUC 0–∞ ; multiple dose: AUC 0–24 V d Volume of distribution † Based on intravenous administration CL Clearance = Dose/AUC 0–∞ F Absolute bioavailability t max h t 1/2 h C max ng/mL AUC ng•h/mL CL/F L/h V d /F L Ganirelix Acetate single dose 1.1 (0.3) 12.8 (4.3) 14.8 (3.2) 96 (12) 2.4 (0.2) † 43.7 (11.4) † Ganirelix Acetate multiple dose 1.1 (0.2) 16.2 (1.6) 11.2 (2.4) 77.1 (9.8) 3.3 (0.4) 76.5 (10.3) Absorption Ganirelix acetate is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of ganirelix acetate following a single 250-mcg subcutaneous injection to healthy female volunteers is 91.1%. Distribution The mean (SD) volume of distribution of ganirelix acetate in healthy females following intravenous administration of a single 250 mcg dose is 43.7 (11.4) liters (L). In vitro protein binding to human plasma is 81.9%. Metabolism Following single-dose intravenous administration of radiolabeled ganirelix acetate to healthy female volunteers, ganirelix acetate is the major compound present in the plasma (50–70% of total radioactivity in the plasma) up to 4 hours and urine (17.1–18.4% of administered dose) up to 24 hours. Ganirelix acetate is not found in the feces. The 1–4 peptide and 1–6 peptide of ganirelix acetate are the primary metabolites observed in the feces. Excretion On average, 97.2% of the total radiolabeled ganirelix acetate dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [ 14 C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing."],"adverse_reactions":["ADVERSE REACTIONS The safety of ganirelix acetate was evaluated in two randomized, parallel-group, multicenter controlled clinical studies. Treatment duration for ganirelix acetate ranged from 1 to 14 days. Table IV represents adverse events (AEs) from first day of ganirelix acetate administration until confirmation of pregnancy by ultrasound at an incidence of ≥ 1% in ganirelix acetate-treated subjects without regard to causality. TABLE IV: Incidence of common adverse events (Incidence ≥ 1% in ganirelix acetate-treated subjects). Completed controlled clinical studies (All-subjects-treated group). Adverse Events Occurring in ≥ 1% Ganirelix Acetate N=794 % (n) Abdominal Pain (gynecological) 4.8 (38) Death Fetal 3.7 (29) Headache 3.0 (24) Ovarian Hyperstimulation Syndrome 2.4 (19) Vaginal Bleeding 1.8 (14) Injection Site Reaction 1.1 (9) Nausea 1.1 (9) Abdominal Pain (gastrointestinal) 1.0 (8) During post-marketing surveillance, rare cases of hypersensitivity reactions, including anaphylaxis (including anaphylactic shock), angioedema and urticaria have been reported with ganirelix acetate, as early as with the first dose (see PRECAUTIONS ). Congenital Anomalies An observational study in more than 1,000 newborns compared the incidence of congenital anomalies in newborns of women administered ganirelix acetate to historical controls of a GnRH agonist. This study demonstrated that the incidence of congenital anomalies in children born after COH treatment in women using ganirelix acetate was comparable with that reported after a COH treatment cycle using a GnRH agonist. The incidence of congenital malformations after some Assisted Reproductive Technologies (ART) [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI. The causal relationship between these congenital anomalies and ganirelix acetate injection is unknown."],"contraindications":["CONTRAINDICATIONS Ganirelix acetate is contraindicated under the following conditions: Known hypersensitivity to ganirelix acetate or to any of its components including dry natural rubber/latex (see HOW SUPPLIED ). Known hypersensitivity to GnRH or any other GnRH analog. Known or suspected pregnancy (see PRECAUTIONS )."],"drug_interactions":["Drug Interactions No formal drug-drug interaction studies have been performed."],"how_supplied_table":["
NDCGanirelix Acetate Injection (250 mcg per 0.5 mL)Package Factor
71288-554-80Disposable, ready for use, prefilled Single-Dose Syringe containing 250 mcg per 0.5 mL of ganirelix acetate, closed with a rubber piston that does not contain latex. Each prefilled syringe is affixed with a 29 gauge x ½-inch needle closed by a rigid needle shield that is not made with natural rubber latex (see CONTRAINDICATIONS and PRECAUTIONS, General).1 syringe per carton
"],"general_precautions":["General Special care should be taken in women with signs and symptoms of active allergic conditions. Cases of hypersensitivity reactions (both generalized and local), including anaphylaxis (including anaphylactic shock), angioedema and urticaria, have been reported with ganirelix acetate, as early as with the first dose, during post-marketing surveillance (see ADVERSE REACTIONS ). If a hypersensitivity reaction is suspected, ganirelix acetate should be discontinued and appropriate treatment administered. In the absence of clinical experience, ganirelix acetate treatment is not advised in women with severe allergic conditions. The rigid needle shield of this product is not made with natural rubber/latex (see CONTRAINDICATIONS and HOW SUPPLIED )."],"storage_and_handling":["Storage Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Protect from light. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex. Brands listed are the trademarks of their respective owners. meitheal ® Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) ©2025 Meitheal Pharmaceuticals Inc. Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing, China 210061 Revised: February 2025 8H6AAM9-03"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient rises in serum LH. At midcycle, a large increase in GnRH release results in an LH surge. The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. Luteinization results in a rise in serum progesterone with an accompanying decrease in estradiol levels. Ganirelix acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix acetate is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix acetate, which is consistent with an antagonist effect. Upon discontinuation of ganirelix acetate, pituitary LH and FSH levels are fully recovered within 48 hours. Pharmacokinetics The pharmacokinetic parameters of single and multiple injections of ganirelix acetate in healthy adult females are summarized in Table I . Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of ganirelix acetate are dose-proportional in the dose range of 125 to 500 mcg. TABLE I: Mean (SD) pharmacokinetic parameters of 250 mcg of ganirelix acetate following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days. t max Time to maximum concentration t ½ Elimination half-life C max Maximum serum concentration AUC Area under the curve; Single dose: AUC 0–∞ ; multiple dose: AUC 0–24 V d Volume of distribution † Based on intravenous administration CL Clearance = Dose/AUC 0–∞ F Absolute bioavailability t max h t 1/2 h C max ng/mL AUC ng•h/mL CL/F L/h V d /F L Ganirelix Acetate single dose 1.1 (0.3) 12.8 (4.3) 14.8 (3.2) 96 (12) 2.4 (0.2) † 43.7 (11.4) † Ganirelix Acetate multiple dose 1.1 (0.2) 16.2 (1.6) 11.2 (2.4) 77.1 (9.8) 3.3 (0.4) 76.5 (10.3) Absorption Ganirelix acetate is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of ganirelix acetate following a single 250-mcg subcutaneous injection to healthy female volunteers is 91.1%. Distribution The mean (SD) volume of distribution of ganirelix acetate in healthy females following intravenous administration of a single 250 mcg dose is 43.7 (11.4) liters (L). In vitro protein binding to human plasma is 81.9%. Metabolism Following single-dose intravenous administration of radiolabeled ganirelix acetate to healthy female volunteers, ganirelix acetate is the major compound present in the plasma (50–70% of total radioactivity in the plasma) up to 4 hours and urine (17.1–18.4% of administered dose) up to 24 hours. Ganirelix acetate is not found in the feces. The 1–4 peptide and 1–6 peptide of ganirelix acetate are the primary metabolites observed in the feces. Excretion On average, 97.2% of the total radiolabeled ganirelix acetate dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [ 14 C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing. Special Populations The pharmacokinetics of ganirelix acetate have not been determined in special populations such as geriatric, pediatric, renally impaired and hepatically impaired patients (see PRECAUTIONS ). Drug-Drug Interactions Formal in vivo or in vitro drug-drug interaction studies have not been conducted (see PRECAUTIONS ). Since ganirelix acetate can suppress the secretion of pituitary gonadotropins, dose adjustments of exogenous gonadotropins may be necessary when used during controlled ovarian hyperstimulation (COH). Clinical Studies The efficacy of ganirelix acetate was established in two adequate and well-controlled clinical studies which included women with normal endocrine and pelvic ultrasound parameters. The studies intended to exclude subjects with polycystic ovary syndrome (PCOS) and subjects with low or no ovarian reserve. One cycle of study medication was administered to each randomized subject. For both studies, the administration of exogenous recombinant FSH [Follistim ® (follitropin beta for injection)] 150 IU daily was initiated on the morning of Day 2 or 3 of a natural menstrual cycle. Ganirelix acetate injection was administered on the morning of Day 7 or 8 (Day 6 of recombinant FSH administration). The dose of recombinant FSH administered was adjusted according to individual responses starting on the day of initiation of ganirelix acetate. Both recombinant FSH and ganirelix acetate were continued daily until at least three follicles were 17 mm or greater in diameter at which time hCG [Pregnyl ® (chorionic gonadotropin for injection, USP)] was administered. Following hCG administration, ganirelix acetate and recombinant FSH administration were discontinued. Oocyte retrieval, followed by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), was subsequently performed. In a multicenter, double-blind, randomized, dose-finding study, the safety and efficacy of ganirelix acetate were evaluated for the prevention of LH surges in women undergoing COH with recombinant FSH. Ganirelix acetate injection doses ranging from 62.5 mcg to 2,000 mcg and recombinant FSH were administered to 332 patients undergoing COH for IVF (see TABLE II ). Median serum LH on the day of hCG administration decreased with increasing doses of ganirelix acetate. Median serum E 2 (17β-estradiol) on the day of hCG administration was 1475, 1110, and 1160 pg/mL for the 62.5, 125, and 250 mcg doses, respectively. Lower peak serum E 2 levels of 823, 703, and 441 pg/mL were seen at higher doses of ganirelix acetate 500, 1,000, and 2,000 mcg, respectively. The highest pregnancy and implantation rates were achieved with the 250 mcg dose of ganirelix acetate as summarized in Table II . TABLE II: Results from the multicenter, double-blind, randomized, dose-finding study to assess the efficacy of ganirelix acetate to prevent premature LH surges in women undergoing COH with recombinant FSH. (Protocol 38602) * Following initiation of ganirelix acetate therapy. Includes subjects who have complied with daily injections ‡ Median values ϒ Mean (standard deviation) † ET: Embryo Transfer Ω As evidenced by ultrasound at 5–6 weeks following ET Daily Dose (mcg) of Ganirelix Acetate 62.5 mcg 125 mcg 250 mcg 500 mcg 1,000 mcg 2,000 mcg No. subjects receiving Ganirelix Acetate 31 66 70 69 66 30 No. subjects with ET † 27 61 62 54 61 27 No. of subjects with LH rise ≥ 10 mIU/mL* 4 6 1 0 0 0 Serum LH (mIU/mL) on day of hCG ‡ 5 th –95 th percentiles 3.6 0.6–19.9 2.5 0.6–11.4 1.7 < 0.25–6.4 1.0 0.4–4.7 0.6 < 0.25–2.2 0.3 < 0.25–0.8 Serum E 2 (pg/mL) on day of hCG ‡ 5 th –95 th percentiles 1475 645–3720 1110 424–3780 1160 384–3910 823 279–2720 703 284–2360 441 166–1940 Vital pregnancy rate Ω per attempt, n (%) 7 (22.6) 17 (25.8) 25 (35.7) 8 (11.6) 9 (13.6) 2 (6.7) per transfer, n (%) 7 (25.9) 17 (27.9) 25 (40.3) 8 (14.8) 9 (14.8) 2 (7.4) Implantation rate (%) ϒ 14.2 (26.8) 16.3 (30.5) 21.9 (30.6) 9.0 (23.7) 8.5 (21.7) 4.9 (20.1) Transient LH rises alone were not deleterious to achieving pregnancy with ganirelix acetate at doses of 125 mcg (3/6 subjects) and 250 mcg (1/1 subjects). In addition, none of the subjects with LH rises ≥ 10 mIU/mL had premature luteinization indicated by a serum progesterone above 2 ng/mL. A multicenter, open-label, randomized study was conducted to assess the efficacy and safety of ganirelix acetate in women undergoing COH. Follicular phase treatment with ganirelix acetate 250 mcg was studied using a luteal phase GnRH agonist as a reference treatment. A total of 463 subjects were treated with ganirelix acetate by subcutaneous injection once daily starting on Day 6 of recombinant FSH treatment. Recombinant FSH was maintained at 150 IU for the first 5 days of ovarian stimulation and was then adjusted by the investigator on the sixth day of gonadotropin use according to individual responses. The results for the ganirelix acetate arm are summarized in Table III . TABLE III: Results from the multicenter, open-label, randomized study to assess the efficacy and safety of ganirelix acetate in women undergoing COH. (Protocol 38607) * Following initiation of ganirelix acetate therapy ‡ Median values § Restricted to subjects with hCG injection ¥ Mean (standard deviation) † ET: Embryo Transfer Ω As evidenced by ultrasound at 12–16 weeks following ET λ Includes one patient who achieved pregnancy with intrauterine induction Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards Ganirelix Acetate 250 mcg No. subjects treated 463 Duration of GnRH analog (days) §, ¥ 5.4 (2.0) Duration of recombinant FSH (days) §, ¥ 9.6 (2.0) Serum E 2 (pg/mL) on day of hCG ‡ 5 th –95 th percentiles 1190 373–3105 Serum LH (mIU/mL) on day of hCG ‡ 5 th –95 th percentiles 1.6 0.6–6.9 No. of subjects with LH rise ≥ 10 mIU/mL * 13 No. of follicles > 11 mm §, ¥ 10.7 (5.3) No. of subjects with oocyte retrieval 440 No. of oocytes ¥ 8.7 (5.6) Fertilization rate 62.1% No. subjects with ET † 399 No. of embryos transferred ¥ 2.2 (0.6) No. of embryos ¥ 6.0 (4.5) Ongoing pregnancy rate Ω, § per attempt, n (%) λ 94 (20.3) per transfer, n (%) 93 (23.3) Implantation rate (%) ¥ 15.7 (29) The mean number of days of ganirelix acetate treatment was 5.4 (2–14). LH Surges The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. In 463 subjects administered ganirelix acetate injection 250 mcg, a premature LH surge prior to hCG administration, (LH rise ≥ 10 mIU/mL with a significant rise in serum progesterone > 2 ng/mL, or a significant decline in serum estradiol) occurred in less than 1% of subjects."],"indications_and_usage":["INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation."],"clinical_studies_table":["
TABLE II: Results from the multicenter, double-blind, randomized, dose-finding study to assess the efficacy of ganirelix acetate to prevent premature LH surges in women undergoing COH with recombinant FSH.
(Protocol 38602)
* Following initiation of ganirelix acetate therapy. Includes subjects who have complied with daily injections
‡ Median values
ϒ Mean (standard deviation)
† ET: Embryo Transfer
Ω As evidenced by ultrasound at 5–6 weeks following ET
Daily Dose (mcg) of Ganirelix Acetate
62.5 mcg125 mcg250 mcg500 mcg1,000 mcg2,000 mcg
No. subjects receiving Ganirelix Acetate316670696630
No. subjects with ET†276162546127
No. of subjects with LH rise ≥ 10 mIU/mL*461000
Serum LH (mIU/mL) on day of hCG‡ 5th–95th percentiles3.6 0.6–19.92.5 0.6–11.41.7 < 0.25–6.41.0 0.4–4.70.6 < 0.25–2.20.3 < 0.25–0.8
Serum E2 (pg/mL) on day of hCG‡ 5th–95th percentiles1475 645–37201110 424–37801160 384–3910823 279–2720703 284–2360441 166–1940
Vital pregnancy rateΩ
per attempt, n (%)7 (22.6)17 (25.8)25 (35.7)8 (11.6)9 (13.6)2 (6.7)
per transfer, n (%)7 (25.9)17 (27.9)25 (40.3)8 (14.8)9 (14.8)2 (7.4)
Implantation rate (%)ϒ14.2 (26.8)16.3 (30.5)21.9 (30.6)9.0 (23.7)8.5 (21.7)4.9 (20.1)
","
TABLE III: Results from the multicenter, open-label, randomized study to assess the efficacy and safety of ganirelix acetate in women undergoing COH.
(Protocol 38607)
* Following initiation of ganirelix acetate therapy
‡ Median values
§ Restricted to subjects with hCG injection
¥ Mean (standard deviation)
† ET: Embryo Transfer
Ω As evidenced by ultrasound at 12–16 weeks following ET
λ Includes one patient who achieved pregnancy with intrauterine induction
Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards
Ganirelix Acetate 250 mcg
No. subjects treated463
Duration of GnRH analog (days)§, ¥5.4 (2.0)
Duration of recombinant FSH (days)§, ¥9.6 (2.0)
Serum E2 (pg/mL) on day of hCG‡ 5th–95th percentiles1190 373–3105
Serum LH (mIU/mL) on day of hCG‡ 5th–95th percentiles1.6 0.6–6.9
No. of subjects with LH rise ≥ 10 mIU/mL*13
No. of follicles > 11 mm§, ¥10.7 (5.3)
No. of subjects with oocyte retrieval440
No. of oocytes¥8.7 (5.6)
Fertilization rate62.1%
No. subjects with ET†399
No. of embryos transferred¥2.2 (0.6)
No. of embryos¥6.0 (4.5)
Ongoing pregnancy rateΩ, §
per attempt, n (%)λ94 (20.3)
per transfer, n (%)93 (23.3)
Implantation rate (%)¥15.7 (29)
"],"pharmacokinetics_table":["
TABLE I: Mean (SD) pharmacokinetic parameters of 250 mcg of ganirelix acetate following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days.
tmax Time to maximum concentration
t½ Elimination half-life
Cmax Maximum serum concentration
AUC Area under the curve; Single dose: AUC0–∞; multiple dose: AUC0–24
Vd Volume of distribution
† Based on intravenous administration
CL Clearance = Dose/AUC0–∞
F Absolute bioavailability
tmax ht1/2hCmax ng/mLAUC ng•h/mLCL/F L/hVd/F L
Ganirelix Acetate single dose1.1 (0.3)12.8 (4.3)14.8 (3.2)96 (12)2.4 (0.2)†43.7 (11.4)†
Ganirelix Acetate multiple dose1.1 (0.2)16.2 (1.6)11.2 (2.4)77.1 (9.8)3.3 (0.4)76.5 (10.3)
"],"adverse_reactions_table":["
TABLE IV: Incidence of common adverse events (Incidence ≥ 1% in ganirelix acetate-treated subjects). Completed controlled clinical studies (All-subjects-treated group).
Adverse Events Occurring in ≥ 1%Ganirelix Acetate N=794 % (n)
Abdominal Pain (gynecological)4.8 (38)
Death Fetal3.7 (29)
Headache3.0 (24)
Ovarian Hyperstimulation Syndrome2.4 (19)
Vaginal Bleeding1.8 (14)
Injection Site Reaction1.1 (9)
Nausea1.1 (9)
Abdominal Pain (gastrointestinal)1.0 (8)
"],"information_for_patients":["Information for Patients Prior to therapy with ganirelix acetate, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see ADVERSE REACTIONS ). Ganirelix acetate should not be prescribed if the patient is pregnant."],"spl_unclassified_section":["meitheal ® Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION After initiating FSH therapy on Day 2 or 3 of the cycle, ganirelix acetate injection 250 mcg may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with ganirelix acetate should be continued daily until the day of hCG administration. When a sufficient number of follicles of adequate size are present, as assessed by ultrasound, final maturation of follicles is induced by administering hCG. The administration of hCG should be withheld in cases where the ovaries are abnormally enlarged on the last day of FSH therapy to reduce the chance of developing OHSS (Ovarian Hyperstimulation Syndrome). Directions for Using Ganirelix Acetate Injection Ganirelix acetate injection is supplied in a single dose, sterile, prefilled syringe and is intended for SUBCUTANEOUS administration only. Air bubble(s) may be seen in the pre-filled syringe. This is expected, and removal of the air bubble(s) is not needed. Wash hands thoroughly with soap and water. The most convenient sites for SUBCUTANEOUS injection are in the abdomen around the navel or upper thigh. The injection site should be swabbed with a disinfectant to remove any surface bacteria. Clean about two inches around the point where the needle will be inserted and let the disinfectant dry for at least one minute before proceeding. With syringe held upward, remove needle cover. Pinch up a large area of skin between the finger and thumb. Vary the injection site a little with each injection. The needle should be inserted at the base of the pinched-up skin at an angle of 45–90° to the skin surface. When the needle is correctly positioned, it will be difficult to draw back on the plunger. If any blood is drawn into the syringe, the needle tip has penetrated a vein or artery. If this happens, withdraw the needle slightly and reposition the needle without removing it from the skin. Alternatively, remove the needle and use a new, sterile, prefilled syringe. Cover the injection site with a swab containing disinfectant and apply pressure; the site should stop bleeding within one or two minutes. Once the needle is correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin is not damaged. Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant. Use the sterile, prefilled syringe only once. Discard the unused portion and dispose of it properly."],"spl_product_data_elements":["Ganirelix Acetate Ganirelix Acetate ganirelix acetate ganirelix mannitol acetic acid sodium hydroxide water"],"clinical_pharmacology_table":["
TABLE I: Mean (SD) pharmacokinetic parameters of 250 mcg of ganirelix acetate following a single subcutaneous (SC) injection (n=15) and daily SC injections (n=15) for seven days.
tmax Time to maximum concentration
t½ Elimination half-life
Cmax Maximum serum concentration
AUC Area under the curve; Single dose: AUC0–∞; multiple dose: AUC0–24
Vd Volume of distribution
† Based on intravenous administration
CL Clearance = Dose/AUC0–∞
F Absolute bioavailability
tmax ht1/2hCmax ng/mLAUC ng•h/mLCL/F L/hVd/F L
Ganirelix Acetate single dose1.1 (0.3)12.8 (4.3)14.8 (3.2)96 (12)2.4 (0.2)†43.7 (11.4)†
Ganirelix Acetate multiple dose1.1 (0.2)16.2 (1.6)11.2 (2.4)77.1 (9.8)3.3 (0.4)76.5 (10.3)
","
TABLE II: Results from the multicenter, double-blind, randomized, dose-finding study to assess the efficacy of ganirelix acetate to prevent premature LH surges in women undergoing COH with recombinant FSH.
(Protocol 38602)
* Following initiation of ganirelix acetate therapy. Includes subjects who have complied with daily injections
‡ Median values
ϒ Mean (standard deviation)
† ET: Embryo Transfer
Ω As evidenced by ultrasound at 5–6 weeks following ET
Daily Dose (mcg) of Ganirelix Acetate
62.5 mcg125 mcg250 mcg500 mcg1,000 mcg2,000 mcg
No. subjects receiving Ganirelix Acetate316670696630
No. subjects with ET†276162546127
No. of subjects with LH rise ≥ 10 mIU/mL*461000
Serum LH (mIU/mL) on day of hCG‡ 5th–95th percentiles3.6 0.6–19.92.5 0.6–11.41.7 < 0.25–6.41.0 0.4–4.70.6 < 0.25–2.20.3 < 0.25–0.8
Serum E2 (pg/mL) on day of hCG‡ 5th–95th percentiles1475 645–37201110 424–37801160 384–3910823 279–2720703 284–2360441 166–1940
Vital pregnancy rateΩ
per attempt, n (%)7 (22.6)17 (25.8)25 (35.7)8 (11.6)9 (13.6)2 (6.7)
per transfer, n (%)7 (25.9)17 (27.9)25 (40.3)8 (14.8)9 (14.8)2 (7.4)
Implantation rate (%)ϒ14.2 (26.8)16.3 (30.5)21.9 (30.6)9.0 (23.7)8.5 (21.7)4.9 (20.1)
","
TABLE III: Results from the multicenter, open-label, randomized study to assess the efficacy and safety of ganirelix acetate in women undergoing COH.
(Protocol 38607)
* Following initiation of ganirelix acetate therapy
‡ Median values
§ Restricted to subjects with hCG injection
¥ Mean (standard deviation)
† ET: Embryo Transfer
Ω As evidenced by ultrasound at 12–16 weeks following ET
λ Includes one patient who achieved pregnancy with intrauterine induction
Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards
Ganirelix Acetate 250 mcg
No. subjects treated463
Duration of GnRH analog (days)§, ¥5.4 (2.0)
Duration of recombinant FSH (days)§, ¥9.6 (2.0)
Serum E2 (pg/mL) on day of hCG‡ 5th–95th percentiles1190 373–3105
Serum LH (mIU/mL) on day of hCG‡ 5th–95th percentiles1.6 0.6–6.9
No. of subjects with LH rise ≥ 10 mIU/mL*13
No. of follicles > 11 mm§, ¥10.7 (5.3)
No. of subjects with oocyte retrieval440
No. of oocytes¥8.7 (5.6)
Fertilization rate62.1%
No. subjects with ET†399
No. of embryos transferred¥2.2 (0.6)
No. of embryos¥6.0 (4.5)
Ongoing pregnancy rateΩ, §
per attempt, n (%)λ94 (20.3)
per transfer, n (%)93 (23.3)
Implantation rate (%)¥15.7 (29)
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Syringe Label NDC 71288- 554 -80 Rx Only Ganirelix Acetate Injection 250 mcg per 0.5 mL For Subcutaneous Use Only 250 mcg Single-Dose Sterile Prefilled Syringe - 29 gauge by 1/2” needle Protect from light. Discard unused portion. PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Syringe Label","PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Carton NDC 71288- 554 -80 1 x 250 mcg Single-Dose Sterile Prefilled Syringe 29 gauge by 1/2” needle Rx Only Ganirelix Acetate Injection 250 mcg per 0.5 mL For Subcutaneous Use Only PRINCIPAL DISPLAY PANEL – Ganirelix Acetate Injection, 250 mcg per 0.5 mL Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis and Mutagenesis, Impairment of Fertility Long-term toxicity studies in animals have not been performed with ganirelix acetate to evaluate the carcinogenic potential of the drug. Ganirelix acetate did not induce a mutagenic response in the Ames test (S. typhimurium and E. coli ) or produce chromosomal aberrations in in vitro assay using Chinese Hamster Ovary cells."]},"tags":[{"label":"Gonadotropin Releasing Hormone Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"H01CC01","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Ovulation induction","category":"indication"},{"label":"Prevention of Luteinizing Hormone Surge when undergoing Controlled Ovarian Hyperstimulation","category":"indication"},{"label":"Organon Usa Organon","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Hormone Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OVARIAN HYPERSTIMULATION SYNDROME","source":"FDA FAERS","actionTaken":"247 reports"},{"date":"","signal":"ASCITES","source":"FDA FAERS","actionTaken":"58 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"37 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"26 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"26 reports"},{"date":"","signal":"PLEURAL EFFUSION","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"ABDOMINAL DISTENSION","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"20 reports"}],"commonSideEffects":[{"effect":"Abdominal Pain (gynecological)","drugRate":"4.8%","severity":"common","_validated":true},{"effect":"Death Fetal","drugRate":"3.7%","severity":"serious","_validated":true},{"effect":"Headache","drugRate":"3.0%","severity":"common","_validated":true},{"effect":"Ovarian Hyperstimulation Syndrome","drugRate":"2.4%","severity":"common","_validated":true},{"effect":"Vaginal Bleeding","drugRate":"1.8%","severity":"mild","_validated":true},{"effect":"Injection Site Reaction","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Abdominal Pain (gastrointestinal)","drugRate":"1.0%","severity":"mild","_validated":true}],"contraindications":["Breastfeeding (mother)","Pregnancy, function"],"specialPopulations":{"Pregnancy":"Contraindicated in pregnant women. Increased incidence of litter resorption in rats and rabbits.","Geriatric use":"Clinical studies did not include sufficient number of subjects aged 65 and over.","Paediatric use":"...","Renal impairment":"...","Hepatic impairment":"..."}},"trials":[],"aliases":[],"company":"Organon Usa Organon","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GANIRELIX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:37:32.417485+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:37:39.513267+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:37:32.434582+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:37:31.047200+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GANIRELIX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:37:40.656766+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:37:29.831053+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:37:29.831071+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:37:42.112873+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Gonadotropin-releasing hormone receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:37:41.217089+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1251/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:37:41.119269+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA214996","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:37:29.831077+00:00"}},"allNames":"ganirelix acetate","offLabel":[],"synonyms":["ganirelix","orgalutran","ganirelix acetate"],"timeline":[{"date":"1999-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ORGANON USA INC to Organon Usa Organon"},{"date":"1999-07-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Organon Usa Inc)"},{"date":"2000-05-16","type":"positive","source":"DrugCentral","milestone":"EMA approval (N.V. Organon)"},{"date":"2025-04-23","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 6 manufacturers approved"}],"aiSummary":"Ganirelix Acetate (GANIRELIX) is a small molecule gonadotropin-releasing hormone receptor antagonist developed by Organon USA INC and currently owned by Organon Usa Organon. It targets the gonadotropin-releasing hormone receptor to prevent luteinizing hormone surge during controlled ovarian hyperstimulation and ovulation induction. GANIRELIX is a generic medication with 7 available manufacturers and is off-patent. It has a half-life of 9.09 hours and was FDA approved in 1999. As a gonadotropin-releasing hormone receptor antagonist, GANIRELIX is used to prevent premature ovulation in women undergoing fertility treatments.","approvals":[{"date":"1999-07-29","orphan":false,"company":"ORGANON USA INC","regulator":"FDA"},{"date":"2000-05-16","orphan":false,"company":"N.V. ORGANON","regulator":"EMA"}],"brandName":"Ganirelix Acetate","ecosystem":[{"indication":"Ovulation induction","otherDrugs":[{"name":"clomifene","slug":"clomifene","company":"Sanofi Aventis Us"},{"name":"follitropin","slug":"follitropin","company":"Serono"}],"globalPrevalence":null},{"indication":"Prevention of Luteinizing Hormone Surge when undergoing Controlled Ovarian Hyperstimulation","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","novelty":"Follow-on","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"}],"moaClass":"Gonadotropin Releasing Hormone Receptor Antagonists","modality":"Small Molecule","drugClass":"Gonadotropin Releasing Hormone Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"GANIRELIX competitively binds to the gonadotropin-releasing hormone receptor, inhibiting the downstream signaling cascade that leads to the release of luteinizing hormone and subsequent ovulation."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-07-29, ORGANON USA INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1279","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GANIRELIX","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GANIRELIX","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:39:43.479433","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:37:46.163113+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cetrorelix","drugSlug":"cetrorelix","fdaApproval":"2000-08-11","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elagolix","drugSlug":"elagolix","fdaApproval":"2018-07-23","patentExpiry":"Sep 1, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"norethisterone","drugSlug":"norethisterone","fdaApproval":"1962-05-21","relationship":"same-class"},{"drugName":"relugolix","drugSlug":"relugolix","fdaApproval":"2020-12-18","patentExpiry":"Sep 29, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ganirelix","indications":{"approved":[{"name":"Ovulation induction","source":"DrugCentral","snomedId":61285001,"regulator":"FDA"},{"name":"Prevention of Luteinizing Hormone Surge when undergoing Controlled Ovarian Hyperstimulation","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"women undergoing controlled ovarian hyperstimulation"}],"offLabel":[],"pipeline":[]},"currentOwner":"Organon Usa Organon","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cetrorelix","brandName":"cetrorelix","genericName":"cetrorelix","approvalYear":"2000","relationship":"same-class"},{"drugId":"elagolix","brandName":"elagolix","genericName":"elagolix","approvalYear":"2018","relationship":"same-class"},{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-class"},{"drugId":"norethisterone","brandName":"norethisterone","genericName":"norethisterone","approvalYear":"1962","relationship":"same-class"},{"drugId":"relugolix","brandName":"relugolix","genericName":"relugolix","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05954962","phase":"PHASE4","title":"Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.","status":"COMPLETED","sponsor":"Instituto Bernabeu","startDate":"2023-12-23","conditions":["IVF"],"enrollment":150,"completionDate":"2025-08-30"},{"nctId":"NCT04983173","phase":"PHASE4","title":"INTEnsity of ovariaN Stimulation and Embryo Quality","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2021-11-23","conditions":["Infertility"],"enrollment":110,"completionDate":"2026-06"},{"nctId":"NCT07409493","phase":"NA","title":"IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols","status":"RECRUITING","sponsor":"Hanoi Medical University","startDate":"2026-01-21","conditions":["Infertility (IVF Patients)","Embryo Morphokinetics","Progestins Primed Ovarian Stimulation"],"enrollment":148,"completionDate":"2028-10"},{"nctId":"NCT06175832","phase":"PHASE4","title":"PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-01-27","conditions":["Ovarian Stimulation","Quality of Life","Preimplantation Genetic Testing","Fertility Preservation"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT05847283","phase":"NA","title":"DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT","status":"RECRUITING","sponsor":"Tam Anh TP. Ho Chi Minh General Hospital","startDate":"2023-06-22","conditions":["Diminished Ovarian Reserve"],"enrollment":730,"completionDate":"2027-12-31"},{"nctId":"NCT04166825","phase":"NA","title":"Ovarian Hyperstimulation and Fibrin Clot Properties.","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2019-11-18","conditions":["Fibrin Blood Clot","Infertility, Female","Endometriosis"],"enrollment":300,"completionDate":"2026-01"},{"nctId":"NCT04265053","phase":"EARLY_PHASE1","title":"Human Cerebral Blood Flow Regulation","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2021-04-12","conditions":["Cerebral Arterial Diseases"],"enrollment":110,"completionDate":"2025-05-31"},{"nctId":"NCT06877429","phase":"","title":"Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?","status":"NOT_YET_RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-12-30","conditions":["Healthy"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07108621","phase":"PHASE3","title":"hCG Priming in Women With Diminished Ovarian Reserve","status":"RECRUITING","sponsor":"Kristine Loessl","startDate":"2025-09","conditions":["Infertility, Female","Ovarian Reserve","In Vitro Fertilization (IVF)"],"enrollment":80,"completionDate":"2031-03-31"},{"nctId":"NCT05994378","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-08-29","conditions":["Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation"],"enrollment":317,"completionDate":"2025-05-02"},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":["Sleep Restriction"],"enrollment":5,"completionDate":"2026-06-24"},{"nctId":"NCT03142893","phase":"PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter y. Liu","startDate":"2017-05-08","conditions":["Sleep Restriction"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT05751252","phase":"EARLY_PHASE1","title":"Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2024-04-17","conditions":["Polycystic Ovary Syndrome"],"enrollment":20,"completionDate":"2025-02-09"},{"nctId":"NCT06280560","phase":"","title":"Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation","status":"RECRUITING","sponsor":"Fundación IVI","startDate":"2024-02-01","conditions":["Endometrial Receptivity"],"enrollment":60,"completionDate":"2025-12-30"},{"nctId":"NCT06745466","phase":"PHASE4","title":"Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women","status":"RECRUITING","sponsor":"University of Delaware","startDate":"2024-11-15","conditions":["Estrogen","Premenopause"],"enrollment":30,"completionDate":"2027-10"},{"nctId":"NCT06091436","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-03-24","conditions":["Infertility"],"enrollment":176,"completionDate":"2024-01-29"},{"nctId":"NCT06637189","phase":"PHASE4","title":"Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.","status":"NOT_YET_RECRUITING","sponsor":"Ginefiv","startDate":"2024-10-15","conditions":["Stimulation in the Ovary","Embryo","Oocyte","Oocyte Retrieval","Fertilization in Vitro","Blastocyst","PGT-A"],"enrollment":144,"completionDate":"2025-12-31"},{"nctId":"NCT00703014","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-13","conditions":["Pregnancy","Neonates"],"enrollment":541,"completionDate":"2009-03-15"},{"nctId":"NCT00702273","phase":"","title":"Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04-19","conditions":["In Vitro Fertilization"],"enrollment":344,"completionDate":"2009-05-31"},{"nctId":"NCT00598208","phase":"PHASE2","title":"A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05-19","conditions":["Fertilization"],"enrollment":325,"completionDate":"2004-03-15"},{"nctId":"NCT00988260","phase":"PHASE2","title":"Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-03","conditions":["Controlled Ovarian Stimulation"],"enrollment":266,"completionDate":"2004-04-12"},{"nctId":"NCT00702806","phase":"PHASE2","title":"Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-01","conditions":["Infertility","In Vitro Fertilization"],"enrollment":99,"completionDate":"2002-10-15"},{"nctId":"NCT06481696","phase":"NA","title":"Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility","status":"RECRUITING","sponsor":"Andros Day Surgery Clinic","startDate":"2024-06-01","conditions":["Unexplained Infertility"],"enrollment":90,"completionDate":"2025-12-31"},{"nctId":"NCT00696800","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06-27","conditions":["In Vitro Fertilization"],"enrollment":1509,"completionDate":"2008-01-15"},{"nctId":"NCT00702845","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12-28","conditions":["Infertility"],"enrollment":397,"completionDate":"2007-11-15"},{"nctId":"NCT01304511","phase":"","title":"Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02","conditions":["Fertilization in Vitro"],"enrollment":711,"completionDate":"2007-12"},{"nctId":"NCT04327934","phase":"EARLY_PHASE1","title":"Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-12-01","conditions":["Polycystic Ovary Syndrome","Hypertension"],"enrollment":28,"completionDate":"2022-06-30"},{"nctId":"NCT04447872","phase":"NA","title":"The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol","status":"UNKNOWN","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":["Infertility","Diminished Ovarian Reserve","IVF"],"enrollment":142,"completionDate":"2025-06"},{"nctId":"NCT04414761","phase":"PHASE3","title":"Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response","status":"COMPLETED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-06-04","conditions":["IVF","GnRH Antagonist","PPOS"],"enrollment":784,"completionDate":"2022-10-10"},{"nctId":"NCT04586686","phase":"NA","title":"Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":["Breast Cancer Female"],"enrollment":41,"completionDate":"2024-12-31"},{"nctId":"NCT04616729","phase":"PHASE1,PHASE2","title":"DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":["Breast Cancer Female"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT03767218","phase":"PHASE3","title":"Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-11-01","conditions":["Infertility, Female"],"enrollment":71,"completionDate":"2022-11-25"},{"nctId":"NCT04108039","phase":"NA","title":"Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.","status":"COMPLETED","sponsor":"Fundacion Dexeus","startDate":"2019-09-25","conditions":["Infertility","IVF","Preimplantation Diagnosis"],"enrollment":44,"completionDate":"2022-05-15"},{"nctId":"NCT02912988","phase":"PHASE3","title":"Letrozole in Stimulated IVF Cycles","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2018-03-01","conditions":["Subfertility"],"enrollment":900,"completionDate":"2023-04-30"},{"nctId":"NCT04071574","phase":"PHASE1,PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":["Female Infertility","Female Infertility Due to Ovulatory Disorder","Premature Ovarian Failure","Polycystic Ovary Syndrome","Female Infertility of Tubal Origin","Ectopic Pregnancy","Salpingitis","Female Infertility Due to Tubal Block","Female Infertility Due to Tubal Occlusion","Hydrosalpinx","Female Infertility - Cervical/Vaginal","Female Infertility Endocrine","Endometriosis","Fibroids","Congenital Uterine Anomaly","Infections Uterine","Female Infertility of Other Origin"],"enrollment":200,"completionDate":"2023-05-05"},{"nctId":"NCT02865460","phase":"PHASE3","title":"Coenzyme Q10 Phase III Trial in Gulf War Illness","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2017-07-24","conditions":["Gulf War Illness","Chronic Fatigue","Ubiquinol","Coenzyme Q10"],"enrollment":100,"completionDate":"2020-12-31"},{"nctId":"NCT04168892","phase":"","title":"Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response","status":"COMPLETED","sponsor":"Andros Day Surgery Clinic","startDate":"2019-09-20","conditions":["Ovarian Response"],"enrollment":160,"completionDate":"2023-01-31"},{"nctId":"NCT03236545","phase":"NA","title":"Menopause Effects on Vascular Function","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2016-07-01","conditions":["Cardiovascular Risk Factor"],"enrollment":48,"completionDate":"2022-11-01"},{"nctId":"NCT02402192","phase":"PHASE4","title":"Type of Gonadotropin and Embryo Kinetics of Development","status":"TERMINATED","sponsor":"IVI Madrid","startDate":"2015-04","conditions":["Infertility"],"enrollment":201,"completionDate":"2016-12"},{"nctId":"NCT03555942","phase":"NA","title":"Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa","status":"COMPLETED","sponsor":"Fundacion Dexeus","startDate":"2018-05-08","conditions":["Infertility"],"enrollment":44,"completionDate":"2021-12-01"},{"nctId":"NCT00725491","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":["Controlled Ovarian Stimulation"],"enrollment":259,"completionDate":"2008-12"},{"nctId":"NCT01599494","phase":"PHASE3","title":"An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2014-03","conditions":["Infertility"],"enrollment":0,"completionDate":"2015-06"},{"nctId":"NCT00702624","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":["Pregnancy","Neonates"],"enrollment":113,"completionDate":"2008-06"},{"nctId":"NCT00724789","phase":"","title":"Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-11","conditions":["Pregnancy","Neonates"],"enrollment":2066,"completionDate":"2005-11"},{"nctId":"NCT00702546","phase":"","title":"Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12","conditions":["In Vitro Fertilization"],"enrollment":102,"completionDate":"2008-12"},{"nctId":"NCT03300518","phase":"NA","title":"Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient","status":"COMPLETED","sponsor":"Reproductive & Genetic Hospital of CITIC-Xiangya","startDate":"2017-11-15","conditions":["Infertility"],"enrollment":552,"completionDate":"2021-08-18"},{"nctId":"NCT04854707","phase":"","title":"An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2020-01-12","conditions":["Reproductive Issues","Reproductive Disorder","Fertility Disorders","Fertility Issues","Gynecologic Disease","IVF"],"enrollment":5484,"completionDate":"2021-01-20"},{"nctId":"NCT04993924","phase":"PHASE4","title":"GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-05-01","conditions":["IVF","Ovarian Cysts"],"enrollment":15,"completionDate":"2023-03-01"},{"nctId":"NCT05071339","phase":"PHASE4","title":"GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-04-01","conditions":["IVF"],"enrollment":15,"completionDate":"2023-03-01"},{"nctId":"NCT03300960","phase":"PHASE3","title":"Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2017-10-20","conditions":["Infertility"],"enrollment":318,"completionDate":"2019-06-25"},{"nctId":"NCT01614067","phase":"PHASE4","title":"Delayed Start to Ovarian Stimulation","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2012-05","conditions":["Diminished Ovarian Reserve","Infertility","In Vitro Fertilization"],"enrollment":30,"completionDate":"2014-09"},{"nctId":"NCT04728659","phase":"PHASE4","title":"Desogestrel Versus GnRH Antagonist in IVF/ICSI","status":"UNKNOWN","sponsor":"Casa di Cura Privata Villa Mafalda","startDate":"2020-10-01","conditions":["IVF","Infertility"],"enrollment":165,"completionDate":"2022-02-28"},{"nctId":"NCT03291821","phase":"NA","title":"DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2017-12-01","conditions":["Infertility, Female"],"enrollment":136,"completionDate":"2020-06-01"},{"nctId":"NCT00608062","phase":"NA","title":"Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-03","conditions":["Arterial Stiffening","Aging","Menopause"],"enrollment":155,"completionDate":"2012-10-25"},{"nctId":"NCT04654741","phase":"PHASE4","title":"The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles","status":"UNKNOWN","sponsor":"Casa di Cura Privata Villa Mafalda","startDate":"2020-09-01","conditions":["IVF","Infertility"],"enrollment":396,"completionDate":"2022-12-31"},{"nctId":"NCT03861715","phase":"","title":"Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.","status":"UNKNOWN","sponsor":"Assisting Nature","startDate":"2017-01","conditions":["Infertility","Premature Ovarian Failure"],"enrollment":180,"completionDate":"2021-12"},{"nctId":"NCT04458454","phase":"","title":"\"Study of the Effects of Serum and Follicular Fluid Relaxin Levels on Ovarian Function in IVF Cycles\"","status":"COMPLETED","sponsor":"D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology","startDate":"2019-12-02","conditions":["Infertility","Reproductive Techniques, Assisted","Oocyte Maturation"],"enrollment":11,"completionDate":"2020-02-20"},{"nctId":"NCT04416607","phase":"NA","title":"Corifollitropin Alpha and Ovarian Response","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2018-06-15","conditions":["Infertility, Female"],"enrollment":300,"completionDate":"2019-01-31"},{"nctId":"NCT00589134","phase":"NA","title":"The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-01","conditions":["Exercise Induced Hyponatremia"],"enrollment":26,"completionDate":"2009-12"},{"nctId":"NCT03051087","phase":"PHASE4","title":"To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-10","conditions":["Controlled Ovarian Stimulation"],"enrollment":255,"completionDate":"2018-03"},{"nctId":"NCT00823472","phase":"PHASE4","title":"Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2009-01","conditions":["in Vitro Fertilization","Ovulation Induction"],"enrollment":147,"completionDate":"2010-10"},{"nctId":"NCT01153581","phase":"PHASE2","title":"Sex Hormones and Orthostatic Tolerance","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-02","conditions":["Orthostatic Intolerance"],"enrollment":109,"completionDate":"2013-05"},{"nctId":"NCT00633555","phase":"","title":"A Comparison of the Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Women Who Are or Who Are Predicted to be Low Responders","status":"COMPLETED","sponsor":"UConn Health","startDate":"2006-07","conditions":["Infertility"],"enrollment":54,"completionDate":"2010-09"},{"nctId":"NCT03477929","phase":"PHASE4","title":"Cetrorelix and Ganirelix Flexible Protocol for (IVF)","status":"UNKNOWN","sponsor":"Università degli Studi 'G. d'Annunzio' Chieti e Pescara","startDate":"2017-11-15","conditions":["Infertility/Sterility"],"enrollment":100,"completionDate":"2019-01-15"},{"nctId":"NCT02069808","phase":"PHASE4","title":"Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation","status":"COMPLETED","sponsor":"Michigan Reproductive Medicine","startDate":"2014-04","conditions":["Egg Donation"],"enrollment":38,"completionDate":"2017-03-08"},{"nctId":"NCT00734279","phase":"EARLY_PHASE1","title":"Follicle-Stimulating Hormone (FSH) and the Onset of Puberty","status":"COMPLETED","sponsor":"University of Utah","startDate":"2006-03","conditions":["Delayed Puberty","Precocious Puberty"],"enrollment":11,"completionDate":"2010-12"},{"nctId":"NCT01385332","phase":"NA","title":"A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-03","conditions":["Stimulation in the Ovary"],"enrollment":10,"completionDate":"2012-09"},{"nctId":"NCT02796105","phase":"PHASE4","title":"Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors","status":"COMPLETED","sponsor":"Fundació Privada Eugin","startDate":"2016-06","conditions":["Infertility"],"enrollment":232,"completionDate":"2017-07-10"},{"nctId":"NCT02118051","phase":"PHASE3","title":"Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2013-09","conditions":["Infertility"],"enrollment":234,"completionDate":"2017-06"},{"nctId":"NCT01590173","phase":"PHASE2,PHASE3","title":"Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2012-01","conditions":["Infertility"],"enrollment":86,"completionDate":"2016-07"},{"nctId":"NCT02429999","phase":"PHASE2","title":"Letrozole in Assisted Reproductive Technology","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2015-04","conditions":["to Evaluate Letrozole as a Modality for Minimal Ovarian Stimulation in ICSI Cycles ."],"enrollment":80,"completionDate":"2017-12"},{"nctId":"NCT00757185","phase":"EARLY_PHASE1","title":"Compromised Microcirculation in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-02","conditions":["Polycystic Ovary Syndrome"],"enrollment":28,"completionDate":"2012-12"},{"nctId":"NCT01816321","phase":"PHASE3","title":"Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2013-03","conditions":["Infertility","Poor Ovarian Response"],"enrollment":150,"completionDate":"2016-05"},{"nctId":"NCT01798862","phase":"PHASE2,PHASE3","title":"Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2013-03","conditions":["Repeated Implantation Failures"],"enrollment":100,"completionDate":"2016-06"},{"nctId":"NCT00756028","phase":"PHASE4","title":"Short Versus Long Protocol for IVF and IVF+ICSI","status":"COMPLETED","sponsor":"Peter Hornnes, MD, DMSc","startDate":"2009-01","conditions":["Infertility","Ovarian Hyperstimulation Syndrome","Quality of Life","Live Birth"],"enrollment":1099,"completionDate":"2015-12"},{"nctId":"NCT01206803","phase":"","title":"Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-09","conditions":["Infertility, Subfertility"],"enrollment":294,"completionDate":"2014-01"},{"nctId":"NCT02635607","phase":"NA","title":"Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol","status":"UNKNOWN","sponsor":"Chong Qing Reproducive and Genetic Institute","startDate":"2016-01","conditions":["Infertility"],"enrollment":200,"completionDate":"2017-03"},{"nctId":"NCT00225433","phase":"PHASE4","title":"Luteal Phase FSH in the IVF Poor Responder","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2005-09","conditions":["Infertility"],"enrollment":20,"completionDate":"2008-06"},{"nctId":"NCT00780858","phase":"","title":"Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2008-10","conditions":["Infertility"],"enrollment":662,"completionDate":"2011-03"},{"nctId":"NCT01645241","phase":"NA","title":"Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation","status":"COMPLETED","sponsor":"Fundacion Dexeus","startDate":"2012-07","conditions":["INFERTILITY","Fertility Preservation","Ovulation Induction","Vitrification","Oocyte Donation"],"enrollment":15,"completionDate":"2013-12"},{"nctId":"NCT01422395","phase":"EARLY_PHASE1","title":"Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development","status":"COMPLETED","sponsor":"Main Line Fertility Center","startDate":"2011-08","conditions":["Fertility"],"enrollment":40,"completionDate":"2013-05"},{"nctId":"NCT01669291","phase":"NA","title":"Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation","status":"COMPLETED","sponsor":"Main Line Fertility Center","startDate":"2012-07","conditions":["Fertility"],"enrollment":43,"completionDate":"2014-05"},{"nctId":"NCT02046655","phase":"PHASE4","title":"Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2011-01","conditions":["Subfertility"],"enrollment":80,"completionDate":""},{"nctId":"NCT00298025","phase":"PHASE4","title":"A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2003-09","conditions":["Infertile Women Undergoing Assisted Reproductive Technology (ART)"],"enrollment":185,"completionDate":"2004-05"},{"nctId":"NCT00823004","phase":"PHASE1,PHASE2","title":"Antagonist/Letrozole in Poor Responders","status":"COMPLETED","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-06","conditions":["Ovarian Stimulation"],"enrollment":120,"completionDate":"2009-10"},{"nctId":"NCT00417066","phase":"PHASE4","title":"Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders","status":"COMPLETED","sponsor":"Eugonia","startDate":"2003-09","conditions":["Infertility","Premature Ovarian Failure"],"enrollment":270,"completionDate":"2006-07"},{"nctId":"NCT00417157","phase":"","title":"Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH","status":"COMPLETED","sponsor":"Eugonia","startDate":"2007-01","conditions":["Infertility","Premature Ovarian Failure"],"enrollment":135,"completionDate":"2012-12"},{"nctId":"NCT00866008","phase":"PHASE4","title":"A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)","status":"TERMINATED","sponsor":"Bart CJM Fauser","startDate":"2008-10","conditions":["In Vitro Fertilization"],"enrollment":34,"completionDate":"2011-01"},{"nctId":"NCT01888744","phase":"PHASE4","title":"Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2010-09","conditions":["Reproductive Endocrinology","Fertility","Optimal Stimulation Protocol"],"enrollment":120,"completionDate":"2013-06"},{"nctId":"NCT00826839","phase":"PHASE4","title":"Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":["Infertility"],"enrollment":0,"completionDate":"2012-01"},{"nctId":"NCT01286051","phase":"NA","title":"Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles","status":"COMPLETED","sponsor":"Houston Fertility Institute","startDate":"2011-01","conditions":["Compare Pregnancy Rates Between FSH Stimulation and FSH and","GnRH Antagonist"],"enrollment":80,"completionDate":"2012-09"},{"nctId":"NCT01636505","phase":"PHASE3","title":"The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol","status":"UNKNOWN","sponsor":"European Hospital","startDate":"2012-09","conditions":["Embryo's Genetic and Chromosomal Quality"],"enrollment":200,"completionDate":"2013-09"},{"nctId":"NCT01218386","phase":"PHASE4","title":"Pretreatment With Estradiol Valerate","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2010-05","conditions":["Infertility"],"enrollment":80,"completionDate":"2012-01"},{"nctId":"NCT01487486","phase":"","title":"Proteomics & Glyco-Proteomic Analysis of Follicular Fluid","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2011-12","conditions":["Polycystic Ovary Syndrome","Normal Volunteers"],"enrollment":30,"completionDate":"2014-01"},{"nctId":"NCT00802360","phase":"PHASE4","title":"MENOPUR® Versus FOLLISTIM®","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2008-12","conditions":["Infertility"],"enrollment":173,"completionDate":"2010-01"},{"nctId":"NCT01424618","phase":"NA","title":"A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs","status":"UNKNOWN","sponsor":"Kelly, Maureen, M.D.","startDate":"2006-01","conditions":["Implantation, Embryo"],"enrollment":20,"completionDate":""},{"nctId":"NCT00434122","phase":"PHASE2","title":"Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-03","conditions":["Infertility, Female"],"enrollment":85,"completionDate":"2007-12"},{"nctId":"NCT01255397","phase":"NA","title":"Proposed Research Protocol For Male Infertility","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2011-01","conditions":["Male Infertility"],"enrollment":50,"completionDate":""},{"nctId":"NCT00985062","phase":"NA","title":"Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2004-10","conditions":["Subfertility"],"enrollment":54,"completionDate":"2006-12"},{"nctId":"NCT00830492","phase":"PHASE4","title":"Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist","status":"COMPLETED","sponsor":"Yazd Research & Clinical Center for Infertility","startDate":"2008-01","conditions":["Ovarian Stimulation"],"enrollment":200,"completionDate":"2008-12"}],"_emaApprovals":[{"date":"2000-05-16","status":"Authorised","company":"N.V. ORGANON"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"Ganirelix Acetate"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Fyremadel"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"GANIRELIX ACETATE"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Ganirelix Acetate"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Ganirelix Acetate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148673","MMSL":"67714","NDDF":"008055","UNII":"IX503L9WN0","VUID":"4021229","CHEBI":"CHEBI:135910","VANDF":"4021229","INN_ID":"6830","RXNORM":"259264","UMLSCUI":"C0073629","chemblId":"CHEMBL1251","ChEMBL_ID":"CHEMBL1251","KEGG_DRUG":"D04302","DRUGBANK_ID":"DB06785","PUBCHEM_CID":"16130957","SNOMEDCT_US":"116102008","IUPHAR_LIGAND_ID":"3877","SECONDARY_CAS_RN":"129311-55-3","MESH_SUPPLEMENTAL_RECORD_UI":"C061018"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1999-","companyName":"Organon Usa Inc","relationship":"Original Developer"},{"period":"present","companyName":"Organon Usa Organon","relationship":"Current Owner"},{"period":"2000","companyName":"N.V. Organon","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"9.09 hours","clearance":"0.63 mL/min/kg","fractionUnbound":"0.18%","volumeOfDistribution":"0.21 L/kg"},"publicationCount":187,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H01CC01","allCodes":["H01CC01"]},"biosimilarFilings":[],"originalDeveloper":"Organon Usa Inc","recentPublications":[{"date":"2025 Nov","pmid":"41426754","title":"IgA Vasculitis With Nephritis Following Controlled Ovarian Stimulation and Oocyte Donation.","journal":"Cureus"},{"date":"2025","pmid":"41142490","title":"Real-World Safety and Effectiveness of Ganirelix for Ovarian Stimulation in Chinese Women: A Multicenter, Prospective, Single-Arm, Observational Study.","journal":"Women's health reports (New Rochelle, N.Y.)"},{"date":"2025","pmid":"40297130","title":"Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study.","journal":"Frontiers in reproductive health"},{"date":"2025 Apr 22","pmid":"40264185","title":"Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).","journal":"BMC pharmacology & toxicology"},{"date":"2025 May","pmid":"40081305","title":"Freeze-all indications in women with subfertility undergoing IVF: a cohort study.","journal":"Reproductive biomedicine online"}],"companionDiagnostics":[],"genericManufacturers":7,"_genericFilersChecked":true,"genericManufacturerList":["Amphastar Pharms Inc","Gland","Lupin Ltd","Meitheal","Qilu","Sun Pharm","Tris Pharma Inc"],"status":"approved","companyName":"Organon Usa Organon","companyId":"organon-usa-organon","modality":"Recombinant protein","firstApprovalDate":"1999","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-07-29T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1999-07-29T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1999-07-29T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1999-07-29T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1999-07-29T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1999-07-29T00:00:00.000Z","mah":"ORGANON USA INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-12-19T00:00:00.000Z","mah":"ORGANON USA ORGANON","brand_name_local":null,"application_number":"NDA021057"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-04-07T00:00:00.000Z","mah":"AMPHASTAR PHARMS INC","brand_name_local":null,"application_number":"ANDA212613"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-06-06T00:00:00.000Z","mah":"MEITHEAL","brand_name_local":null,"application_number":"ANDA214996"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-11-16T00:00:00.000Z","mah":"LUPIN LTD","brand_name_local":null,"application_number":"ANDA216075"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-26T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":null,"application_number":"ANDA204246"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":6,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:37:46.163113+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}